Oak Thistle LLC Has $1.21 Million Position in Encompass Health Corporation (NYSE:EHC)

Oak Thistle LLC reduced its stake in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 47.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,899 shares of the company's stock after selling 10,827 shares during the quarter. Oak Thistle LLC's holdings in Encompass Health were worth $1,205,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Colonial Trust Co SC acquired a new position in Encompass Health during the fourth quarter worth $29,000. Transce3nd LLC acquired a new stake in shares of Encompass Health in the fourth quarter valued at $40,000. Arlington Trust Co LLC increased its stake in shares of Encompass Health by 22.9% in the first quarter. Arlington Trust Co LLC now owns 671 shares of the company's stock valued at $68,000 after buying an additional 125 shares in the last quarter. C M Bidwell & Associates Ltd. increased its stake in shares of Encompass Health by 73.6% in the fourth quarter. C M Bidwell & Associates Ltd. now owns 750 shares of the company's stock valued at $69,000 after buying an additional 318 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in shares of Encompass Health in the fourth quarter valued at $72,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the sale, the executive vice president owned 79,710 shares of the company's stock, valued at approximately $9,149,910.90. This trade represents a 11.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark J. Tarr sold 118,384 shares of Encompass Health stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the sale, the chief executive officer directly owned 527,070 shares in the company, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 132,663 shares of company stock worth $16,034,082 in the last 90 days. Corporate insiders own 2.00% of the company's stock.

Analyst Ratings Changes

EHC has been the subject of a number of research reports. UBS Group raised their target price on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research note on Monday, April 28th. Barclays lifted their price objective on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Royal Bank Of Canada lifted their price objective on Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. Stephens upgraded Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price objective for the company in a research report on Thursday, June 5th. Finally, Wall Street Zen lowered Encompass Health from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $131.50.

Encompass Health Trading Up 0.4%

EHC traded up $0.40 during midday trading on Friday, reaching $107.53. 675,621 shares of the company were exchanged, compared to its average volume of 1,004,874. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.06 and a current ratio of 1.06. Encompass Health Corporation has a one year low of $82.74 and a one year high of $123.13. The stock has a market capitalization of $10.84 billion, a P/E ratio of 22.22, a PEG ratio of 2.19 and a beta of 0.88. The stock's 50-day simple moving average is $117.99 and its 200 day simple moving average is $107.50.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The business had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. During the same quarter in the previous year, the business posted $1.12 EPS. Encompass Health's revenue for the quarter was up 10.6% on a year-over-year basis. As a group, analysts forecast that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Wednesday, October 1st will be issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.71%. The ex-dividend date of this dividend is Wednesday, October 1st. This is a boost from Encompass Health's previous quarterly dividend of $0.17. Encompass Health's payout ratio is 14.05%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.